Trial of Psilocybin versus Escitalopram for Depression

On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients.

Secondary outcomes generally favored psilocybin over escitalopram

Minocycline as an Adjunctive Treatment for Depression

has been shown to improve symptoms of schizophrenia and bipolar depression, ostensibly by reducing inflammatory responses that contribute to symptoms. The current investigators pooled data from two 12-week, randomized, placebo-controlled, minocycline treatment trials for 112 patients with major depression typically in their mid-40s (60% men).

Associations Between Prenatal Cannabis Exposure and Childhood Outcomes

Results From the ABCD Study This study suggests that prenatal cannabis exposure and its correlated factors are associated with greater risk for psychopathology during middle childhood. Cannabis use during pregnancy should be discouraged.